| Title |
Role of oral teriflunomide in the management of multiple sclerosis
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, April 2013
|
| DOI | 10.2147/ndt.s31248 |
| Pubmed ID | |
| Authors |
Radu Tanasescu, Nikos Evangelou, Cris S Constantinescu |
| Abstract |
The landscape of the treatment of relapsing-remitting multiple sclerosis is changing fast. Several oral treatments have shown benefit and generate much interest because of the convenience of their administration. Two oral compounds, fingolimod and teriflunomide, have been approved in relapsing-remitting multiple sclerosis, while others have completed Phase III trials and are awaiting review for registration. Teriflunomide is a pyrimidine synthesis inhibitor with selective immunomodulatory and immunosuppressive properties that have shown consistent efficacy in clinical trials, and a good safety profile. This paper provides an overview of the mechanisms of action and efficacy and safety results from clinical trials with this drug. The role of teriflunomide in the treatment of relapsing-remitting multiple sclerosis is discussed. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 43 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 6 | 13% |
| Other | 5 | 11% |
| Student > Bachelor | 5 | 11% |
| Student > Master | 4 | 9% |
| Researcher | 3 | 7% |
| Other | 8 | 18% |
| Unknown | 14 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 36% |
| Neuroscience | 4 | 9% |
| Agricultural and Biological Sciences | 3 | 7% |
| Chemistry | 2 | 4% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Other | 4 | 9% |
| Unknown | 15 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 May 2013.
All research outputs
#20,110,957
of 25,584,565 outputs
Outputs from Neuropsychiatric Disease and Treatment
#2,171
of 3,120 outputs
Outputs of similar age
#157,420
of 213,424 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#29
of 48 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,120 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,424 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.